Johnson & Johnson: shareholders and insiders

JNJNYSEHealthcare · Pharmaceutical Preparations

Price

$285.75

November 13, 2026Market cap $689B

What Ploutos Investor adds for Johnson & Johnson

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 15, 2025 to Nov 13, 2026, from their own Form 4 filings.

14 Form 4s

Bought on the market

$257.7K

1 person

Sold on the market

$154M

10 people

From Nov 15, 2025 to Nov 15, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan0%
  • The rest100%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 15, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $154M by 10 people

  • 2025: bought $257.7K by 1 person, no sales
  • 2026: no buys, sold $154M by 10 people
  • Nov 12, 2026Elizabeth ForminardEVP, Chief Legal Officer
    Kind
  • Nov 12, 2026Elizabeth ForminardEVP, Chief Legal Officer
    Kind
  • Sep 2, 2026Timothy SchmidEVP, WW Chair, MedTech
    Kind
  • Sep 2, 2026Timothy SchmidEVP, WW Chair, MedTech
    Kind
  • Sep 2, 2026Timothy SchmidEVP, WW Chair, MedTech
    Kind
  • Sep 2, 2026Timothy SchmidEVP, WW Chair, MedTech
    Kind
  • Aug 17, 2026Jennifer L TaubertEVP, WWC. Innovative Medicine
    Kind
  • Aug 17, 2026Jennifer L TaubertEVP, WWC. Innovative Medicine
    Kind
  • Aug 13, 2026Joaquin DuatoCEO and Chairman of the Board
    Kind
  • Aug 13, 2026Joaquin DuatoCEO and Chairman of the Board
    Kind
  • Aug 13, 2026Joaquin DuatoCEO and Chairman of the Board
    Kind
  • Aug 6, 2026Elizabeth ForminardEVP, Chief Legal Officer
    Kind
  • Aug 6, 2026Elizabeth ForminardEVP, Chief Legal Officer
    Kind
  • Aug 6, 2026Elizabeth ForminardEVP, Chief Legal Officer
    Kind
  • Aug 5, 2026Joaquin DuatoCEO and Chairman of the Board
    Kind
  • Aug 5, 2026Joaquin DuatoCEO and Chairman of the Board
    Kind
  • Jul 20, 2026Vanessa BroadhurstEVP, Global Corp Affairs
    Kind
  • Jul 20, 2026Vanessa BroadhurstEVP, Global Corp Affairs
    Kind
  • Jul 20, 2026Vanessa BroadhurstEVP, Global Corp Affairs
    Kind
  • Jun 11, 2026Kathryn E WengelEVP, Chief TO and Risk Officer
    Kind
  • Jun 11, 2026Kathryn E WengelEVP, Chief TO and Risk Officer
    Kind
  • Feb 27, 2026Robert J DeckerVP Corporate Controller
    Kind
  • Feb 20, 2026Timothy SchmidEVP, WW Chair, MedTech
    Kind
  • Feb 18, 2026Timothy SchmidEVP, WW Chair, MedTech
    Kind
  • Feb 18, 2026Timothy SchmidEVP, WW Chair, MedTech
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 11, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by JNJ's officers and directors from 2006 up to November 14, 2025, 20 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

1 Holders over 5%May 1, 2026 Latest filing
  • Vanguard Capital Management
    Share of class7.49%
Fell to 5% or less (1)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • The Vanguard Group0.00%Mar 26, 202613G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Jun 30, 2026 quarter end
  • Fairfax Financial (Watsa)
    In the quarter
  • Bridgewater (Dalio)
    In the quarter-4.0%
  • AQR Capital
    In the quarter-18%
  • Citadel Advisors (Griffin)
    In the quarter-22%
  • D.E. Shaw
    In the quarter-10%
  • Millennium Mgmt (Englander)
    In the quarter+3.2%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 0.70% of its shares outstanding were held short, -24.0% since the report before.

Shares held short
16.77M
0.70%
Since the report before22.07M on Sep 30, 2026
-24.0%
2.0
8.52M
More days to cover thanof 4,578 US-listed companies with enough volume
24%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 14.53M
  • Nov 15, 2023: Shares held short 13.19M
  • Nov 30, 2023: Shares held short 15.00M
  • Dec 15, 2023: Shares held short 15.40M
  • Dec 29, 2023: Shares held short 12.47M
  • Jan 12, 2024: Shares held short 15.01M
  • Jan 31, 2024: Shares held short 12.30M
  • Feb 15, 2024: Shares held short 10.96M
  • Feb 29, 2024: Shares held short 14.85M
  • Mar 15, 2024: Shares held short 15.84M
  • Mar 28, 2024: Shares held short 15.94M
  • Apr 15, 2024: Shares held short 16.56M
  • Apr 30, 2024: Shares held short 17.67M
  • May 15, 2024: Shares held short 17.43M
  • May 31, 2024: Shares held short 19.93M
  • Jun 14, 2024: Shares held short 19.56M
  • Jun 28, 2024: Shares held short 21.17M
  • Jul 15, 2024: Shares held short 17.99M
  • Jul 31, 2024: Shares held short 18.85M
  • Aug 15, 2024: Shares held short 19.81M
  • Aug 30, 2024: Shares held short 21.13M
  • Sep 13, 2024: Shares held short 23.03M
  • Sep 30, 2024: Shares held short 19.74M
  • Oct 15, 2024: Shares held short 18.66M
  • Oct 31, 2024: Shares held short 18.11M
  • Nov 15, 2024: Shares held short 17.48M
  • Nov 29, 2024: Shares held short 18.54M
  • Dec 13, 2024: Shares held short 17.57M
  • Dec 31, 2024: Shares held short 16.46M
  • Jan 15, 2025: Shares held short 17.20M
  • Jan 31, 2025: Shares held short 18.76M
  • Feb 14, 2025: Shares held short 18.35M
  • Feb 28, 2025: Shares held short 23.10M
  • Mar 14, 2025: Shares held short 24.87M
  • Mar 31, 2025: Shares held short 19.15M
  • Apr 15, 2025: Shares held short 21.02M
  • Apr 30, 2025: Shares held short 19.68M
  • May 15, 2025: Shares held short 22.80M
  • May 30, 2025: Shares held short 19.22M
  • Jun 13, 2025: Shares held short 16.33M
  • Jun 30, 2025: Shares held short 15.82M
  • Jul 15, 2025: Shares held short 18.27M
  • Jul 31, 2025: Shares held short 17.14M
  • Aug 15, 2025: Shares held short 18.52M
  • Aug 29, 2025: Shares held short 18.84M
  • Sep 15, 2025: Shares held short 22.05M
  • Sep 30, 2025: Shares held short 18.18M
  • Oct 15, 2025: Shares held short 20.63M
  • Oct 31, 2025: Shares held short 19.53M
  • Nov 14, 2025: Shares held short 20.12M
  • Nov 28, 2025: Shares held short 23.91M
  • Dec 15, 2025: Shares held short 23.97M
  • Dec 31, 2025: Shares held short 20.43M
  • Jan 15, 2026: Shares held short 21.33M
  • Jan 30, 2026: Shares held short 19.56M
  • Feb 13, 2026: Shares held short 20.77M
  • Feb 27, 2026: Shares held short 25.09M
  • Mar 13, 2026: Shares held short 23.33M
  • Mar 31, 2026: Shares held short 22.27M
  • Apr 15, 2026: Shares held short 19.67M
  • Apr 30, 2026: Shares held short 22.35M
  • May 15, 2026: Shares held short 23.04M
  • May 29, 2026: Shares held short 23.41M
  • Jun 15, 2026: Shares held short 26.69M
  • Jun 30, 2026: Shares held short 26.58M
  • Jul 15, 2026: Shares held short 27.43M
  • Jul 31, 2026: Shares held short 25.41M
  • Aug 14, 2026: Shares held short 21.59M
  • Aug 31, 2026: Shares held short 21.67M
  • Sep 15, 2026: Shares held short 21.19M
  • Sep 30, 2026: Shares held short 22.07M
  • Oct 15, 2026: Shares held short 16.77M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading31.5% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 31.5% of the shares in the reported trades were short sales, against 35.0% in the 14 before.

Last 14 sessionsOct 27, 2026 – Nov 13, 2026
31.5%
The 14 beforeOct 7, 2026 – Oct 26, 2026
35.0%
Change
-3.5 pts
Short sales a dayon average, of 2.65M shares
832.4K
More than atof 3,649 US-listed companies, same days
6%
Median of alleight in ten from 34.6% to 63.4%
50.1%
  • Oct 7, 2026: Short sales 30.6%
  • Oct 8, 2026: Short sales 33.2%
  • Oct 9, 2026: Short sales 31.1%
  • Oct 12, 2026: Short sales 43.9%
  • Oct 13, 2026: Short sales 48%
  • Oct 14, 2026: Short sales 31.9%
  • Oct 15, 2026: Short sales 27.6%
  • Oct 16, 2026: Short sales 23.8%
  • Oct 19, 2026: Short sales 41.7%
  • Oct 20, 2026: Short sales 32%
  • Oct 21, 2026: Short sales 24%
  • Oct 22, 2026: Short sales 35%
  • Oct 23, 2026: Short sales 34%
  • Oct 26, 2026: Short sales 34.2%
  • Oct 27, 2026: Short sales 43.6%
  • Oct 28, 2026: Short sales 29.8%
  • Oct 29, 2026: Short sales 33.4%
  • Oct 30, 2026: Short sales 23.4%
  • Nov 2, 2026: Short sales 25.6%
  • Nov 3, 2026: Short sales 26.9%
  • Nov 4, 2026: Short sales 22.3%
  • Nov 5, 2026: Short sales 34.3%
  • Nov 6, 2026: Short sales 37%
  • Nov 9, 2026: Short sales 41.8%
  • Nov 10, 2026: Short sales 20.5%
  • Nov 11, 2026: Short sales 25.6%
  • Nov 12, 2026: Short sales 45.6%
  • Nov 13, 2026: Short sales 46.1%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

834.2K Insiders' shares0.03% Of the company
  • Joaquin DuatoCEO and Chairman of the Board
    Directly276.0K
  • Jennifer L TaubertEVP, WWC. Innovative Medicine
    Directly194.5K
  • Kathryn E WengelEVP, Chief TO and Risk Officer
    Directly114.3K
  • Joseph J WolkExec VP, CFO
    Directly39.0K
  • James D. SwansonEVP, CIO
    Directly25.7K
  • Timothy SchmidEVP, WW Chair, MedTech
    Directly25.4K
  • Robert J DeckerVP Corporate Controller
    Directly23.7K
  • Vanessa BroadhurstEVP, Global Corp Affairs
    Directly23.0K
  • Elizabeth ForminardEVP, Chief Legal Officer
    Directly17.0K
  • John C ReedEVP, Innovative Medicine, R&D
    Directly12.9K
  • John G MorikisDirector
    Directly1,849
  • Mark A WeinbergerDirector
    Directly1,000
  • Eugene A. WoodsDirector
    Directly–

A lower bound: it counts only the 13 officers and directors with a market trade since Nov 16, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

10b5-1 trading plans

Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.

0 Adopted in the last 12 months15 Filings read
  • Peter FasoloExecutive Vice President, Chief Human Resources Officer
    What happenedAdoptedAug 31, 2023
    Shares25.0K

As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.

Executive pay

From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.

FY2025 Latest year6 Years on record

$33M

Actually paid: $68M

$12M

Actually paid: $25M

$152

Peers: $189

Annual relative total shareholder return

From the proxy statement (DEF 14A) of Mar 11, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A

The shareholders' vote on pay

The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.

94.7% For in 20266 Votes on record
  • 2026Apr 28, 2026
    For
    94.7%
  • 2025Apr 30, 2025
    For
    91.6%
  • 2024Apr 29, 2024
    For
    90.5%
  • 2023May 1, 2023
    For
    93.2%
  • 2022Apr 29, 2022
    For
    86.0%
  • 2021Apr 26, 2021
    For
    56.7%

From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.

The ETFs that hold it

Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

59 ETFs holding it10.64% The largest weight (XLV)
  • XLVState Street(R) Health Care Select Sector SPDR(R) ETF
    Weight in the fund10.64%
  • IYHiShares U.S. Healthcare ETF
    Weight in the fund10.17%
  • VHTVanguard Health Care Index Fund
    Weight in the fund8.75%
  • IXJiShares Global Healthcare ETF
    Weight in the fund7.04%
  • SPMOInvesco S&P 500 Momentum ETF
    Weight in the fund4.65%
  • MTUMiShares MSCI USA Momentum Factor ETF
    Weight in the fund3.54%
  • DGROiShares Core Dividend Growth ETF
    Weight in the fund3.07%
  • MGVVanguard Morningstar Mega Cap Value Index Fund
    Weight in the fund2.96%
  • DIADIA
    Weight in the fund2.90%
  • VIGVanguard Dividend Appreciation Index Fund
    Weight in the fund2.67%

59 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

4,681 Managers, Q2 2026$457B Value of their positions
  • Q3 2025: Managers 4,201
  • Q4 2025: Managers 4,549
  • Q1 2026: Managers 4,655
  • Q2 2026: Managers 4,681

Institutional investors by quarter

The fund managers holding JNJ, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 4,681 managers held 1.80B shares, worth $457B. During the quarter 219 opened a position, 193 closed one, 1,941 added and 1,853 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter-0.6%
  • Vanguard Capital Management
    In the quarter+0.4%
  • State Street
    In the quarter+0.2%
  • Vanguard Portfolio Management
    In the quarter+1.3%
  • Geode Capital Management
    In the quarter-0.1%
  • JPMorgan Chase
    In the quarter-7.6%
  • Morgan Stanley
    In the quarter+0.2%
  • Norges Bank
    In the quarter-4.9%
  • State Farm Mutual Automobile Insurance
    In the quarter
  • Northern Trust
    In the quarter-1.8%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

The full analysis

What do Johnson & Johnson's filings show?

Who buys and sells is one part of Johnson & Johnson's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about JNJ's shareholders

Didn't find what you were looking for?

Ask us
Have JNJ's insiders bought or sold?

From Jun 11, 2026 to Nov 13, 2026 Johnson & Johnson's insiders bought 0 and sold $74M of shares on the market. 0% of the sales were under set 10b5-1 plans.

Which well-known managers hold JNJ?

6 of the managers we track held the shares on Jun 30, 2026. The largest position was AQR Capital's, worth $739M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.